COMMENT
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Note of clarification of data in the paper entitled "Interferon gamma +874 T/A polymorphism increases the risk of cervical cancer: evidence from a meta-analysis".

We read with great interest the paper entitled "Interferon gamma +874 T/A polymorphism increases the risk of cervical cancer: evidence from a meta-analysis" published online by Sun et al. Their results suggest that interferon gamma ( IFNG) gene +874 T/A polymorphism might contribute to women's susceptibility to cervical cancer. They also found that IFNG +874 T/A polymorphism is associated with increased cervical cancer risk in Asian female population. The result is encouraging. Nevertheless, several key issues are worth noticing. We re-evaluate the association between IFNG +874 T/A polymorphism and cervical cancer risk by performing an updated meta-analysis based on 2777 cases and 2542 controls of 11 studies. We found that IFNG +874 T/A polymorphism was not significantly associated with cervical cancer risk in overall population. We also observed that the polymorphism was associated with enhanced cervical cancer risk in Asian population and was relevant to increased squamous cell cervical cancer risk.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app